1289646-76-9

Basic information

• Product Name: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid
• Synonyms: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid
• CAS NO: 1289646-76-9
• Molecular Formula: C₁₅H₂₁NO₆S
• Molecular Weight: 343.39534
• EINECS: -0
• Mol File: 1289646-76-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 572.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 3.74±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(1289646-76-9)
• EPA Substance Registry System: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(1289646-76-9)

Safety Data

• Hazardous Substances Data: 1289646-76-9(Hazardous Substances Data)

Usage

General Description

(S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid is a chemical compound with the molecular formula C16H23NO6S. It is a derivative of propanoic acid and contains an amino group protected by a tert-butoxycarbonyl (Boc) group. It also has a phenyl group with a methylsulfonyl substituent. (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid is commonly used in organic synthesis as a building block for creating other compounds, particularly in the pharmaceutical and biotechnology industries. Its structural features make it a useful intermediate for the synthesis of various biologically active molecules. Additionally, it has potential applications in medicinal chemistry and drug discovery.

Upstream product

• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 20277-69-4 sodium methansulfinate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67-71-0 dimethylsulfone 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 

Downstream Products

• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.